TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, today announced that it will begin making applications for Canadians in need to access psilocybin-assisted and MDMA-assisted therapy through Health Canada’s Special Access Program (SAP).

Source

Previous articleEntheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee
Next articlePharmaTher Announces Publication of Research Data for KETABET™